Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation
Barabino, L
;Galitzia, A;Caocci, G;Greco, M;Mulas, O;Costa, A;La Nasa, GLast
2022-01-01
Abstract
Due to the high mortality rate of COVID-19, the assessment of BNT162b2 SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech) efficacy in allogeneic hematopoietic stem cell transplant (HSCT) recipients is mandatory.File | Size | Format | |
---|---|---|---|
8984-8989-1.pdf open access
Type: Author’s Accepted Manuscript AAM, Post-print, (version accepted by the publisher)
Size 463.14 kB
Format Adobe PDF
|
463.14 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.